Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Molecular & Cellular Proteomics : MCP|January 20, 2011
Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometryJeffrey R Whiteaker, Lei Zhao, Susan E Abbatiello, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.Nature Biotechnology|June 21, 2011
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular diseaseTerri A Addona, Xu Shi, Hasmik Keshishian, et al.Cancer|November 17, 2005
Angiosarcoma of the breastStephan A Vorburger, Yan Xing, Kelly K Hunt, et al.American Journal of Hematology|December 6, 2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignanciesEric H Rubin, Dinesh P de Alwis, Isabelle Pouliquen, et al.Journal of Translational Medicine|November 14, 2009
Evolutionary concepts in biobanking - the BC BioLibraryPeter H Watson, Janet E Wilson-McManus, Rebecca O Barnes, et al.Thrombosis and Haemostasis|March 12, 2009
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage programLeon Poller, Michelle Keown, Saied Ibrahim, et al.Scientific Reports|January 27, 2023
LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinomaSho Sato, Michael Gillette, Pamela R de Santiago, et al.Blood|May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogsAdam S Sperling, Michael Burgess, Hasmik Keshishian, et al.Pageof 6